- Home
- LEGN vs MDGL Comparison
LEGN vs MDGL Comparison
Compare LEGN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- MDGL
- Stock Information
- Founded
- LEGN 2014
- MDGL 2011
- Country
- LEGN United States
- MDGL United States
- Employees
- LEGN N/A
- MDGL N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- LEGN Health Care
- MDGL Health Care
- Exchange
- LEGN Nasdaq
- MDGL Nasdaq
- Market Cap
- LEGN 7.0B
- MDGL 7.1B
- IPO Year
- LEGN 2020
- MDGL N/A
- Fundamental
- Price
- LEGN $37.19
- MDGL $335.39
- Analyst Decision
- LEGN Strong Buy
- MDGL Buy
- Analyst Count
- LEGN 12
- MDGL 14
- Target Price
- LEGN $79.50
- MDGL $352.08
- AVG Volume (30 Days)
- LEGN 1.2M
- MDGL 427.2K
- Earning Date
- LEGN 03-11-2025
- MDGL 02-26-2025
- Dividend Yield
- LEGN N/A
- MDGL N/A
- EPS Growth
- LEGN N/A
- MDGL N/A
- EPS
- LEGN N/A
- MDGL N/A
- Revenue
- LEGN $627,241,000.00
- MDGL $180,133,000.00
- Revenue This Year
- LEGN $121.45
- MDGL $217.05
- Revenue Next Year
- LEGN $65.49
- MDGL $84.73
- P/E Ratio
- LEGN N/A
- MDGL N/A
- Revenue Growth
- LEGN 119.97
- MDGL N/A
- 52 Week Low
- LEGN $30.17
- MDGL $189.00
- 52 Week High
- LEGN $69.24
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- LEGN 54.69
- MDGL 51.38
- Support Level
- LEGN $33.94
- MDGL $322.00
- Resistance Level
- LEGN $35.77
- MDGL $350.00
- Average True Range (ATR)
- LEGN 1.82
- MDGL 21.38
- MACD
- LEGN -0.11
- MDGL -1.00
- Stochastic Oscillator
- LEGN 61.16
- MDGL 45.99
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.